Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,008 public trials 572 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Completed

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

NCT01058434

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • University of South Alabama / Mitchell Cancer Institute Dept. of Mitchell Cancer Inst. Mobile, Alabama, United States
  • Central Hematology Oncology Medical Group Alhambra, California, United States
  • Central Coast Medical Oncology Corporation Santa Maria, California, United States
  • St. Jude Heritage Medical Group Virginia Crosson Cancer Center Yorba Linda, California, United States
View all 30 locations
View Trial Details
Completed

Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma

NCT00532389

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Innovative Medical Research of South Florida Dept.ofInnovativeMedResearch Miami Shores, Florida, United States
  • Dana Farber Cancer Institute Clinical Research Coordinator Boston, Massachusetts, United States
  • Hackensack University Medical Center Multiple Myeloma Division Hackensack, New Jersey, United States
  • Swedish Medical Center Dept.ofSwedishMedicalCtr. Seattle, Washington, United States
View all 16 locations
View Trial Details
Completed

Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

NCT01302886

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • Highlands Oncology Group Dept of Highlands Oncology Grp Fayetteville, Arkansas, United States
  • H. Lee Moffitt Cancer Center & Research Institute SC - 3 Tampa, Florida, United States
  • Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2) Atlanta, Georgia, United States
  • Indiana University Indiana Univ Indianapolis, Indiana, United States
View all 13 locations
View Trial Details
Completed

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

NCT02144038

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(SC) Houston, Texas, United States
  • Seattle Cancer Care Alliance Oncology Dept Seattle, Washington, United States
  • University of Wisconsin / Paul P. Carbone Comp Cancer Center Dept of Onc. Madison, Wisconsin, United States
  • Novartis Investigative Site Prahran, Victoria, Australia
View Trial Details
Completed

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

NCT01337752

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Female Urogenital Diseases, +19 more
Locations
  • University Chicago Hospital Dept. of Univ of Chicago (2) Chicago, Illinois, United States
  • Medical Oncology Associates, PS Spokane, Washington, United States
  • Novartis Investigative Site Valencia, Spain
  • Novartis Investigative Site Madrid, Spain
View Trial Details
Completed

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

NCT00708292

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Mayo Clinic - Arizona Cancer Clinical Research Unit Scottsdale, Arizona, United States
  • Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3) San Antonio, Texas, United States
  • Novartis Investigative Site Melbourne, Australia
  • Novartis Investigative Site Frankfurt, Germany
View Trial Details
Completed

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT01456689

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Novartis Investigative Site Chicago, Illinois, United States
  • Novartis Investigative Site Ann Arbor, Michigan, United States
  • Novartis Investigative Site Rochester, Minnesota, United States
  • Novartis Investigative Site Houston, Texas, United States
View Trial Details

Related conditions